Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine vs Sugammadex for Residual Neuromuscular Blockade
NCT03292965Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Incidence of postoperative residual curarization (TOF ratio > 0.9). Started Sep 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03292965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292965.